Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Combination of Lenalidomide and Rituximab Overcomes Rituximab Resistance in Patients with Indolent B-cell and Mantle Cell Lymphomas.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Apr 2015

Chong Elise A, Ahmadi Tahamtan, Aqui Nicole A, Svoboda Jakub, Nasta Sunita D, Mato Anthony R, Walsh Kristy M, Schuster Stephen J

Abstract excerpt

PURPOSE: Lenalidomide, an immunomodulatory agent that enhances antibody-dependent cell-mediated cytotoxicity, has the potential to synergize with rituximab, an anti-CD20 mAb. We hypothesized that the addition of lenalidomide to rituximab would improve clinical outcomes in patients with B-cell lymphomas who were previously rituximab resistant, defined as no response to or progression of lymphoma within 6 months of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Tumor Burden
Share to Lenalidomide

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lymphoma, B-Cell

Share to Lymphoma, Mantle-Cell

Share to Receptors, IgG

Share to Retreatment

Share to Rituximab

Share to Thalidomide

Source

Identifiers

PMID: 25632047
DOI: 10.1158/1078-0432.CCR-14-2221

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Combination of Lenalidomide and Rituximab Overcomes Rituximab Resistance in Patients with Indolent B-cell and Mantle Cell Lymphomas.PMID 25632047Read ↗

Rituximab resistance.Semantic proximity Read ↗

Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial.Semantic proximity Read ↗

Development of rituximab-resistant B-NHL clones: an in vitro model for studying tumor resistance to monoclonal antibody-mediated immunotherapy.Semantic proximity Read ↗

Lenalidomide and rituximab for the initial treatment of patients with chronic lymphocytic leukemia: a multicenter clinical-translational study from the chronic lymphocytic leukemia research consortium.Semantic proximity Read ↗

Management of Drug Resistance in Mantle Cell LymphomaSemantic proximity Read ↗

Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study.Semantic proximity Read ↗

Lenalidomide overcomes the resistance to third-generation CD19-CAR-T cell therapy in preclinical models of diffuse large B-cell lymphomaSemantic proximity Read ↗

Activity of lenalidomide in mantle cell lymphoma can be explained by NK cell-mediated cytotoxicity.Semantic proximity Read ↗

Bendamustine and rituximab in combination with lenalidomide in patients with chronic lymphocytic leukemia.Semantic proximity Read ↗

Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression.Semantic proximity Read ↗

A multicentre phase II study of vorinostat in patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma.Semantic proximity Read ↗

Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.